Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study
暂无分享,去创建一个
W. Pirker | G. Kovacs | I. Lachmann | T. Voigtländer | U. Unterberger | A. Perret‐Liaudet | A. Berghoff | Uta Wagner | A. Geneste | K. Flach
[1] H. Budka,et al. Intracellular processing of disease-associated α-synuclein in the human brain suggests prion-like cell-to-cell spread , 2014, Neurobiology of Disease.
[2] B. Hyman,et al. A Luminex Assay Detects Amyloid β Oligomers in Alzheimer’s Disease Cerebrospinal Fluid , 2013, PloS one.
[3] J. Trojanowski,et al. CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease , 2013, Acta Neuropathologica.
[4] P. Calabresi,et al. Cerebrospinal fluid biomarkers in Parkinson disease , 2013, Nature Reviews Neurology.
[5] L. Minthon,et al. Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy , 2013, PloS one.
[6] R. Sakakibara,et al. Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease , 2012, Alzheimer disease and associated disorders.
[7] H. Budka,et al. An antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology , 2012, Acta Neuropathologica.
[8] P. Calabresi,et al. Cerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias , 2011, Movement disorders : official journal of the Movement Disorder Society.
[9] Brit Mollenhauer,et al. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.
[10] H. Budka,et al. Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases. , 2010, Clinical neuropathology.
[11] H. Budka,et al. Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics , 2010, Acta Neuropathologica.
[12] R. Gross. Detection of elevated levels of -synuclein oligomers in CSF from patients with Parkinson disease , 2010 .
[13] W. M. van der Flier,et al. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.
[14] T. Tokuda,et al. CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease , 2009, Brain Research.
[15] B. Mollenhauer,et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration , 2008, Experimental Neurology.
[16] M Emre,et al. Treatment of dementia associated with Parkinson's disease. , 2007, Parkinsonism & related disorders.
[17] T. Tokuda,et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. , 2006 .
[18] M. Onofrj,et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.
[19] D. Allsop,et al. Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[20] T. Tokuda,et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. , 2006, Biochemical and biophysical research communications.
[21] Michel Goedert,et al. Alpha-synuclein and neurodegenerative diseases , 2001, Nature Reviews Neuroscience.